Detecting Medication Errors in Pharmacovigilance Database: Capacities and Limits

Alj, Loubna; Touzani, M; Benkirane, R; Soulaymani, R.

doi:10.2165/00002018-200730100-00110

Cited by 11 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Morocco, a retrospective analysis of the database showed that 14% of all suspected adverse drug reactions were preventable. Medication errors associated with preventable adverse drug effects and related to the medication use system occurred most often at the stages of prescribing (36%) and administration (34%) [5].…”

mentioning

confidence: 99%

Medication errors: pharmacovigilance centres in detection and prevention

Bencheikh

Benabdallah

2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. Detecting medication errors needs collaboration between various organizations, such as patient safety institutions, pharmacovigilance centres, and poison control centres. In order to evaluate the input of pharmacovigilance centres and poison control centres in detecting and evaluating medication errors a pilot project was initiated by the World Alliance for Patient Safety in collaboration with the Uppsala Monitoring Centre; the Moroccan pharmacovigilance centre acted as project coordinator. As part of this project, a questionnaire on detecting medication errors was circulated to pharmacovigilance centres and poison control centres around the world, in order to assess their ability to detect and analyse medication errors. 2. The results showed that through their databases pharmacovigilance centres can detect, identify, analyse, and classify medication errors and carry out root cause analysis, which is an important tool in preventing medication errors. 3. The duties of pharmacovigilance centres in preventing medication errors include informing health-care professionals about the importance of reporting such errors and creating a culture of patient safety. Pharmacovigilance centres aim to prevent medication errors in collaboration with poison control centres. Such collaboration allows improved detection and improved preventive strategies. In addition, collaboration with regulatory authorities is important in finalizing decisions. 4. Collaboration between pharmacovigilance centres and poison control centres should be strengthened and bridges need to be built linking pharmacovigilance centres, poison control centres, and organizations dedicated to patient safety, in order to avoid duplication of workload.

show abstract

mentioning

confidence: 99%

Medication errors: pharmacovigilance centres in detection and prevention

Bencheikh

Benabdallah

2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The WHO has highlighted the importance of identifying MEs and now working towards expansion of existing roles of pharmacovigilance centres which are beginning to work collaboratively to identify MEs by either prospective or retrospective manner 14,15 . In our study, we revealed 9.8% ADRs (n=64) are preventable resulting due to medication errors, while Aji et al, study revealed that 14.4% were considered preventable and Desiree et al, study revealed that 4.3% were considered preventable ADRs which occurred due to MEs 16,17 .…”

Section: Statistical Analysis: By Microsoft Excel Software 2007 In Numentioning

confidence: 45%

Untitled

2018

IJPSR

View full text Add to dashboard Cite

Introduction: Despite the traditional focus on adverse drug reactions, pharmacovigilance centres have recently been identified as a potentially rich and important source of medication error (ME) data. The aim of this study is to identify ME from adverse drug reaction (ADRs) reports. Materials and methods: A retrospective analysis of ADR reports notified to adverse drug reaction monitoring centre of tertiary care teaching hospital and medical college during January 2014 to December 2016 was done. Those reports which had inappropriate information were excluded. Result: A total of 651 reports met the inclusion criteria and were reviewed, The mean age and weight of patients experienced ADRs due to ME was 32.6 ± 16.1 years and 51.9 ± 17.3 kg respectively, among which 35 men and 39 women. Regarding type of medication errors, most of them were related to monitoring errors (56.2%) followed by prescribing errors (37.5%). Considering categories of ME, 73.4% was into category E which was related to temporary harm to the patient. Majority of ADR reports were mild in nature and produce mild temporary harm to the patients. Conclusion: Explore new role of pharmacovigilance centre to identify medication error which is preventable and indirectly improve quality of health care system and ensuring patient safety.

show abstract

“…Of all the sources of data for drug safety monitoring, the spontaneous reporting systems provide the highest volume of information at the lowest maintenance cost [3], and have proven their value in the early detection of patient safety issues related either to the products themselves or to their use [4]. The most important function of spontaneous reporting systems is the early identification of signals [5] and formulation of hypotheses, leading to further confirmatory investigations or sometimes regulatory warnings and changes of product information leaflets.…”

Section: Spontaneous Reporting Systemmentioning

confidence: 99%

WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems

et al. 2013

View full text Add to dashboard Cite

Globally, national pharmacovigilance systems rely on spontaneous reporting in which suspected adverse drug reactions (ADRs) are reported to a national coordinating centre by health professionals, manufacturers or patients. Spontaneous reporting systems are the easiest to establish and the cheapest to run but suffer from poor-quality reports and underreporting. It is difficult to estimate rates and frequencies of ADRs through spontaneous reporting. Public health programmes need to quantify and characterize risks to individuals and communities from their medicines, to minimize harm and improve use, to sustain public confidence in the programmes, and to track problems due to medication errors and poor quality medicines. Additional methods are therefore needed to monitor the quantitative aspects of medicine safety, to better identify specific risk factors and high-risk groups, and to characterize ADRs associated with specific medicines and in specific populations. The present paper introduces two methods, cohort event monitoring and targeted spontaneous reporting, that are being implemented by the WHO, in its public health programmes, to complement spontaneous reporting. The advantages and disadvantages of these methods and how each can be applied in clinical practice are discussed.

show abstract

Detecting Medication Errors in Pharmacovigilance Database: Capacities and Limits

Cited by 11 publications

References 0 publications

Medication errors: pharmacovigilance centres in detection and prevention

Medication errors: pharmacovigilance centres in detection and prevention

Untitled

WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems

Contact Info

Product

Resources

About